This study is for adults with early-stage non-small cell lung cancer (NSCLC) that can be removed by surgery. Researchers want to see if adding a third drug, REGN7075, to cemiplimab (an immunotherapy) and platinum-based chemotherapy works better than cemiplimab plus chemotherapy alone. The study will also look at side effects, how the treatments affect surgery, and how much of the drugs are in your blood. You may be able to join if you have Stage II-IIIB NSCLC, measurable disease, and can provide a tumor sample. The main goal is to see how many participants have a major pathologic response (meaning most of the cancer cells are gone) after treatment, measured up to 12 weeks.

Study design

This is an interventional study planning to enroll 120 adult participants. The specific phase of the study is not mentioned.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, major pathologic response, is measured up to 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.